Momegalen (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene expression. This suppresses the release of inflammatory mediators, decreases leukocyte infiltration, and limits vascular leakage, providing potent anti‑inflammatory and immunosuppressive effects at the site of application.

The specific dose and frequency of Momegalen are determined by the prescribing clinician based on the severity of the skin condition, the area to be treated and patient factors. Patients should follow the exact instructions provided on the prescription label.

Safety data for Momegalen in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this medication.

To request Momegalen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Momegalen (mometasone furoate) is a high‑potency glucocorticoid, offering stronger anti‑inflammatory action than low‑potency agents such as hydrocortisone. Compared with other high‑potency steroids like clobetasol, it may have a slightly lower risk of skin atrophy while delivering comparable efficacy for many dermatoses.

Momegalen should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excessive moisture, direct sunlight and heat sources to maintain stability and potency.

Momegalen is applied topically to the affected skin area in a thin layer, usually once or twice daily as directed by a physician. The skin should be clean and dry before application, and hands should be washed after use to avoid inadvertent exposure.

Serious risks include skin atrophy, hypopigmentation, secondary infections, and systemic cortisol suppression when used over large areas or for prolonged periods. Patients should report any unusual thinning of the skin, persistent redness, or signs of infection to their healthcare provider promptly.

Momegalen should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation excipients, in patients with untreated bacterial, fungal or viral skin infections, and in those where systemic corticosteroid therapy is contraindicated unless specifically advised by a clinician.